Vaxil Announces Brokered Private Placement - Seite 2

The Units, the Shares and Warrants comprising the Units and the Agents' Warrants will be subject to a hold period of four months and one day from their date of issue in accordance with applicable securities laws.

The Company expects the Offering to close on or around June 25, 2020.

“This financing comes at a critical time for our company. These additional funds will allow us to more aggressively advance our preclinical research program including the COVID-19 vaccine, whilst continuing to pursue our other pipeline candidates such as vaccines for other infectious diseases and our ongoing work in Oncology.  We look forward to our continued collaborations with the Tel-Aviv Medical Centre where are progressing our COVID-19 research and Ben Gurion University for their role in our oncology program,” said David Goren, Vaxil’s Chairman and Chief Executive Officer, and continued “Our focus is to pursue the generation of meaningful data to validate our platform and pursue additional partnerships and collaborations.”

ABOUT VAXIL

Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.

Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit, Vaxil’s proprietary bioinformatic approach. These signal pepdies induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.